Education
About Us
Working with TipRanks
Follow Us
ProQR (PRQR)
NASDAQ:PRQR
Top Page
ProQR
(NASDAQ:PRQR)
47Neutral
Positive Factors
Market Opportunity
PRQR's RNA editing therapy, targeting the bile acid transporter for cholestatic diseases, addresses a multi-billion-dollar market, presenting a substantial long-term opportunity.
Strategic Partnerships
Partnership with Eli Lilly underscores platform value and opens the door for milestone payments down the road.
Negative Factors
Timeline Delays
The timing for the Company's lead ADAR therapeutic, AX-0810, to enter the clinic has been pushed out 2 quarters.
ProQR (PRQR) vs. S&P 500 (SPY)
Market Cap
$190.93M
Dividend YieldN/A
Average Volume (3M)366.49K
Price to Earnings (P/E)―
Beta (1Y)1.03
Revenue Growth346.02%
EPS Growth28.96%
CountryUS
Employees157
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.32
Shares Outstanding103,203,735
10 Day Avg. Volume540,794
30 Day Avg. Volume366,494
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)14.92
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.50Price Target Upside413.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
ProQR Business Overview & Revenue Model
Company DescriptionProQR Therapeutics N.V. is a biotechnology company focused on the development of RNA-based therapies to treat genetic disorders. With a primary focus on rare diseases, particularly those affecting the eye, ProQR leverages its innovative RNA editing technology to address unmet medical needs. The company is headquartered in the Netherlands and operates within the biopharmaceutical sector, developing transformative medicines designed to correct genetic mutations at the RNA level.
How the Company Makes MoneyProQR makes money primarily through the development and commercialization of its RNA-based therapeutic products. The company generates revenue through licensing agreements and collaborations with other pharmaceutical and biotechnology companies, which may include upfront payments, milestone payments, and royalties on net sales. Additionally, ProQR may receive funding through grants and investments from healthcare-focused venture capital firms and public offerings. Strategic partnerships with larger pharmaceutical companies play a significant role in supporting ProQR’s research and development efforts, providing both financial resources and expertise to advance their pipeline of RNA therapies.
ProQR Financial Statement Overview
Summary
ProQR exhibits strengths in revenue growth and maintaining a solid cash position. However, the company faces challenges in profitability and cash flow generation. The balance sheet shows moderate leverage, but ongoing losses and negative cash flows present potential risks. Overall, while there are positive aspects, financial stability requires improvements in profitability and cash flow management.Income Statement
ProQR's TTM revenue shows a significant increase compared to previous periods, indicating positive revenue growth. However, the company continues to experience negative EBIT and net income, impacting overall profitability. While gross profit margin is positive, net profit margins remain negative, suggesting challenges in achieving profitability.54
Neutral
Balance Sheet
The balance sheet reflects a reasonable level of equity relative to total assets, with an equity ratio of 23.38%. However, the debt-to-equity ratio stands at 0.70, indicating a moderate level of leverage. The company maintains a healthy cash position, reducing net debt effectively, which provides financial stability.60
Neutral
Cash Flow
ProQR's cash flow statement shows a decline in free cash flow, with negative operating cash flow and free cash flow. The free cash flow to net income and operating cash flow to net income ratios are unfavorable, indicating inefficiencies in converting net income into cash flows.48
Neutral
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 17.86M | 6.51M | 4.04M | 1.35M | 0.00 | 1.93M | Gross Profit |
| 16.45M | 6.38M | 1.56M | 1.35M | -2.19M | -114.89M | EBIT |
| -29.79M | -31.86M | -64.72M | -57.19M | -42.37M | -57.45M | EBITDA |
| -26.85M | -24.10M | -56.46M | -54.95M | -136.56M | -174.27M | Net Income Common Stockholders |
| -23.85M | -28.12M | -64.89M | -61.68M | -46.61M | -56.75M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 105.58M | 118.92M | 94.78M | 187.52M | 75.84M | 111.95M | Total Assets |
| 110.23M | 137.88M | 171.32M | 209.58M | 98.73M | 117.53M | Total Debt |
| 9.39M | 19.73M | 21.97M | 60.37M | 34.28M | 13.56M | Net Debt |
| -96.19M | -99.19M | -72.80M | -127.15M | -41.56M | -98.39M | Total Liabilities |
| 17.55M | 96.49M | 106.21M | 96.35M | 42.18M | 23.70M | Stockholders Equity |
| 92.92M | 41.39M | 65.50M | 113.83M | 57.09M | 94.33M |
| Cash Flow | Free Cash Flow | ||||
| -36.78M | 20.18M | -69.22M | -26.50M | -47.98M | -44.55M | Operating Cash Flow |
| -32.62M | 21.55M | -68.51M | -26.01M | -47.06M | -43.97M | Investing Cash Flow |
| 3.49M | 4.28M | -702.00K | -425.00K | -924.00K | -580.00K | Financing Cash Flow |
| -2.21M | -2.27M | -30.89M | 136.83M | 14.50M | 50.20M |
ProQR Technical Analysis
Negative
1.85
Price Trends
2.32
Negative
2.90
Negative
2.38
Negative
Market Momentum
-0.14
Positive
32.46
Neutral
6.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRQR, the sentiment is Negative. The current price of 1.85 is below the 20-day moving average (MA) of 2.26, below the 50-day MA of 2.32, and below the 200-day MA of 2.38, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 32.46 is Neutral, neither overbought nor oversold. The STOCH value of 6.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRQR.
ProQR Risk Analysis
ProQR disclosed 81 risk factors in its most recent earnings report. ProQR reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ProQR Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $9.77B | 42.25 | 19.71% | ― | 52.97% | ― | |
56 Neutral | $4.15B | ― | 33.08% | ― | -13.97% | 43.51% | |
49 Neutral | $5.25B | ― | -93.03% | ― | -10.48% | -18.79% | |
49 Neutral | $6.90B | -0.08 | -53.01% | 2.43% | 24.84% | -3.06% | |
47 Neutral | $190.93M | ― | -67.62% | ― | 346.02% | 28.96% | |
46 Neutral | $302.72M | ― | -71.87% | ― | -15.14% | 15.84% | |
42 Neutral | $129.44M | ― | -98.10% | ― | -58.64% | -40.05% |
* Healthcare Sector Average
Performance Comparison
PRQR
ProQR
1.85
-0.48
-20.60%
IONS
Ionis Pharmaceuticals
33.41
-9.75
-22.59%
SRPT
Sarepta Therapeutics
99.77
-22.19
-18.19%
PTCT
PTC Therapeutics
52.59
21.80
70.80%
RGNX
RegenXBio
6.11
-16.36
-72.81%
EDIT
Editas Medicine
1.47
-7.12
-82.89%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.